Tatalaksana Takikardia Ventrikel
DOI:
https://doi.org/10.55175/cdk.v50i9.723Keywords:
Implantable cardioverter-defibrillator, kateter ablasi, obat aritmia, takikardia ventrikelAbstract
Takikardia ventrikel (TV), yang sering terjadi pada pasien dengan kelainan struktur jantung, dapat meningkatkan risiko kematian mendadak. Penyebab paling sering adalah parut miokard akibat infark. Bentuk yang lebih benigna terjadi tanpa adanya gangguan struktur jantung. Penanganan TV meliputi penanganan kegawatdaruratan dan pencegahan berulang dengan obat anti-aritmia dan terapi device. Beberapa pasien dapat dilakukan pemasangan implantable cardioverter-defibrillator. Kateter ablasi juga dapat menjadi pilihan.
Ventricular tachycardia (VT) most commonly occurs in structural heart disease, associated with increased risk of sudden death. The most common cause is myocardial scar from prior infarct. More benign forms occur in the absence of structural heart disease. Treatment involves both emergency management and prevention of recurrence with antiarrhythmic drugs and device therapy. Appropriately selected patients may be candidates for implantable cardioverter-defibrillator. Catheter ablation may also be an option.
Downloads
References
Basu-Ray I. Vetricular tachycardia: Recognition and management for internist. Medicine Update [Internet]. 2005. Available from: http://www.apiindia.org/pdf/medicine_update_2005/chapter_15.pdf
Wangko LC, Edmond LJ. Pemetaan dan ablasi pada takikardia ventrikel akibat parut. J Biomedik. 2015;7(Supl 3):12-22.
Koplan BA, Stevenson WG. Ventricular tachycardia and sudden cardiac death. Mayo Clinic Proc. 2009; 84(3):289-97
Sydell and Arnold Miller Family Heart and Vascular Institute. Ventricular tachycardia overview and treatment guide. Cleveland Clinic. 2010: Rev 8/10
Nathani P, Sheetal S, Lokhandwala Y. Ventricular tachycardia in structurally normal heart: Recognition and management. Supplement of Japi. 2007;55:33-8.
Roberts-Thomson KC, Lau DH, Sanders P. The diagnosis and management of ventricular arrhythmias. Nat Rev Cardiol. 2011;8(6):311-21. Doi: 10.1038/nrcardio.2011.15
House AM, Giguere S. How to diagnose and treat ventricular tachycardia. AAEP Proc Medicine-Respiratory/Cardiovascular. 2009;55:308-12
Riva M, Watanabe M, Zeppenfeld K. Twelve-Lead ECG of ventricular tachycardia in structural heart disease. Circ Arrhythm Electrophysiol. 2015;8:951-62. doi: 10.1161/CIRCEP.115.002847
Schereieck J, Hessling G, Pustowoit A, Schmitt C. Ventricular tachycardia. Darmstadt: Springer; 2006.
Lilly LS. Pathophysiology of heart disease. Lippincott Williams & Wilkins; 2011
Stevonson WG. Current treatment of ventricular arrhythmias: State of the art. Gordon K Moe Lecture. Heart Rhythm. 2013;10:1919-26
Priori SG, Blomstrom-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, et al. 2015 ESC guideline for management of patient with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2015;36:2793-867. doi: 10.1093/eurheartj/ehv316
Pedersen CT, Kay GN, Kalman J, Borggrefe M, Della-Bella P, Dickfeld T, Dorian P, et al. EHRA/HRS/APHRS expert consensus on ventricular arrhythmias. Heart Rhythm. 2014(11):166-96
Ajay N. Management of ventricular tachycardia: Identification and therapy guide for multidisciplinary doctors. Gujarat Med J. 2010;65(2):36-42
William ES, Viswanathan MN. Current and emerging antiarrhythmic drug therapy for ventricular tachycardia. Cardiol Ther. 2013;2:27-46. doi: 10.1007/s40119-013-0012-5
Piccini JP, Schulte PJ, Pieper KS, Mehta RH, White HD, Van de Werf F, et al. Antiarrhythmic drug therapy for sustained ventricular arrhythmias complicating acute myocardial infarction. Crit Care Med. 2011;39(1):78-83. doi: 101097/CCM.0b013e3181fd6ad7
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2018 https://creativecommons.org/licenses/by-nc/4.0/
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
